2021 CMSC Annual Meeting

Tag: Canada

Platform-Neuroimaging

A Description of Real-World MRI Acquired in Patients with Multiple Sclerosis: Preliminary Insights from FlywheelMS

Background: Magnetic resonance imaging (MRI) in the context of routine care is an important tool that can inform clinical decisions in...

Read More

Platform-Neuroimaging

Upper Cervical Spinal Cord Myelin Content and Atrophy across the Spectrum of MS Subtypes

Background: The Canadian Prospective Cohort Study to Understand Progression in People Living with MS (CanProCo) aims to better understand...

Read More

Platform-Rehabilitation

Stakeholder Recommendations for a Dyadic Physical Activity Intervention for People with Moderate-to-Severe Multiple Sclerosis and Their Care-Partners: A Modified e-Delphi Study.

Background: People with moderate-to-severe multiple sclerosis (MS) and their family caregivers do not engage in sufficient physical...

Read More

Platform-Disease Modifying Therapies

Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...

Read More

Platform-Disease Management

COVID-19 in Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease Patients in North America

Background: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised...

Read More

Platform-Neuroimaging

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...

Read More